Advanced Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Advanced Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major advanced heart failure markets reached a value of US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.9 Billion by 2034, exhibiting a growth rate (CAGR) of 14.02% during 2024-2034.

The advanced heart failure market has been comprehensively analyzed in IMARC's new report titled "Advanced Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Advanced heart failure refers to a critical stage of cardiac disease where the heart's ability to pump blood efficiently becomes severely compromised. This condition typically arises as a progression from earlier stages of heart failure and is characterized by a significant reduction in the heart's pumping capacity. Common symptoms of the ailment encompass breathlessness, even during rest, extreme fatigue, fluid retention leading to swelling in the legs and ankles (edema), and difficulty performing routin e activities due to decreased exercise tolerance. Patients might also experience frequent hospitalizations due to worsening indications and increased vulnerability to complications. Diagnosing advanced heart failure involves a comprehensive evaluation by healthcare professionals. This usually includes a thorough medical history review, a physical investigation to assess the severity of indications and signs of fluid retention, and often the use of imaging techniques like echocardiography to detect cardiac structure and function. Blood workups are also recommended to determine markers of heart stress and damage.

The escalating cases of various underlying causes, such as cardiomyopathy, coronary artery disease, and long-standing hypertension that can induce functional and structural changes in the myocardium, are primarily driving the advanced heart failure market. In addition to this, the inflating utilization of tailored cardiac rehabilitation programs, which are recognized for their efficacy in enhancing cardiac function, optimizing exercise tolerance, and improving the overall quality of life, is also creating a positive outlook for the market. Moreover, the widespread adoption of pharmacological approaches like angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors, on account of their several advantages, including halting disease progression, reducing the strain on the heart, and lessening symptoms of the illness, is further bolstering the market growth. Apart from this, the rising usage of gene-editing technologies, since they aim to rectify genetic anomalies responsible for cardiac disorders, thereby presenting an exciting avenue for potential therapeutic breakthroughs, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine, involving techniques such as tissue engineering and stem cell therapy to repair damaged cardiac tissue and reverse the course of the ailment, is expected to drive the advanced heart failure market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the advanced heart failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for advanced heart failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the advanced heart failure market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the advanced heart failure market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the advanced heart failure market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current advanced heart failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the advanced heart failure market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the advanced heart failure market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the advanced heart failure market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of advanced heart failure across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced heart failure by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced heart failure by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with advanced heart failure across the seven major markets?
What is the size of the advanced heart failure patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of advanced heart failure?
What will be the growth rate of patients across the seven major markets?

Advanced Heart Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for advanced heart failure drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the advanced heart failure market?
What are the key regulatory events related to the advanced heart failure market?
What is the structure of clinical trial landscape by status related to the advanced heart failure market?
What is the structure of clinical trial landscape by phase related to the advanced heart failure market?
What is the structure of clinical trial landscape by route of administration related to the advanced heart failure market?